<?xml version="1.0" encoding="UTF-8"?>
<p>Convalescent plasma has been used for various viral infections including H1N1 influenza, SARS, and MERS with some evidence of potential benefit [
 <xref rid="B172-vaccines-08-00224" ref-type="bibr">172</xref>,
 <xref rid="B173-vaccines-08-00224" ref-type="bibr">173</xref>]. Hyperimmune globulin products are used in adults and children to prevent or to treat viral infections such as cytomegalovirus, varicella zoster, and respiratory syncytial virus. Plasma from individuals who have recovered from Covid-19 containing antibodies to SARS-CoV-2 or specific antibody preparations derived from plasma may suppress viremia and modify the inflammatory response [
 <xref rid="B174-vaccines-08-00224" ref-type="bibr">174</xref>]. In two small case series of critically ill patients with Covid-19, administration of convalescent plasma containing neutralizing antibody was followed by clinical improvement in all patients without safety concerns [
 <xref rid="B175-vaccines-08-00224" ref-type="bibr">175</xref>,
 <xref rid="B176-vaccines-08-00224" ref-type="bibr">176</xref>]. No experience with hyperimmune globulin products in Covid-19 has been published so far. 
</p>
